GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio Inc (HKSE:01530) » Definitions » Short Percentage of Float

3SBio (HKSE:01530) Short Percentage of Float


View and export this data going back to 2015. Start your Free Trial

What is 3SBio Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of 3SBio's Short Percentage of Float

For the Biotechnology subindustry, 3SBio's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

3SBio's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3SBio's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where 3SBio's Short Percentage of Float falls into.


3SBio (HKSE:01530) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio Inc (HKSE:01530) » Definitions » Short Percentage of Float
Comparable Companies
HKSE:06826 HKSE:06990 HKSE:02162 HKSE:09688 HKSE:09969 HKSE:01541 HKSE:06660 HKSE:09966 HKSE:01952 HKSE:02315 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
83B:Germany
Address
No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN, 110027
Website
https://www.3sbio.com
3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2021, it reported revenue of CNY 6.3 billion. Approximately 90% of its revenue is derived from four core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), rhEPO, and Mandi (minoxidil). With the exception of minoxidil, an over-the-counter drug, the others are all older generation biologics. Most of the pipeline candidates are "me-too" drugs and in general are still at an early stage.

3SBio (HKSE:01530) Headlines

No Headlines